A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM)

被引：78

作者：

Cloughesy, T. F.

Prados, M. D.

Wen, P. Y.

Mikkelsen, T.

Abrey, L. E.

Schiff, D.

Yung, W. K.

Maoxia, Z.

Dimery, I.

Friedman, H. S.

机构：

[1] Univ Calif Los Angeles, Los Angeles, CA USA

[2] Ctr Comprehens Canc, San Francisco, CA USA

[3] Henry Ford Hlth System, Detroit, MI USA

[4] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[5] Univ Virginia, Charlottesville, VA USA

[6] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[7] Genentech Inc, San Francisco, CA 94080 USA

[8] Duke Univ, Durham, NC USA

来源：

关键词：

D O I：

10.1200/jco.2008.26.15_suppl.2010b

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2010b

引用

页数：1